Actively Recruiting
Real-World Study of Satralizumab for Early Treatment of Neuromyelitis Optica Spectrum Disorder Attacks
Led by Junwei Hao, MD · Updated on 2026-08-13
50
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a multicenter, prospective cohort study to evaluate the real-world effectiveness and safety of Satralizumab for patients with Neuromyelitis Optica Spectrum Disorder NMOSD during the early phase of an NMOSD attack. This study aims to provide more effective treatment options by assessing Satralizumabs impact on various clinical and functional measures over time. Participants will receive Satralizumab through subcutaneous injections following a dosing schedule recommended in the prescribing information. The loading dose of 120 mg is given at Weeks 0, 2, and 4, followed by a maintenance dose of 120 mg every 4 weeks, with treatment lasting for at least 24 weeks. This treatment is part of routine care, and patients are observed as they receive their medication. During the study, participants will be followed up at baseline, 3 months, and 6 months. Researchers will collect data on disability scores EDSS, functional status modified Rankin Scale, quality of life EQ-5D, daily living activities ADL, relapse events, safety information, and exploratory measures such as blood inflammatory markers and visual function. This comprehensive monitoring aims to assess the treatments real-world outcomes and safety over a 24-week period.
CONDITIONS
Brief Title
A Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in NMOSD
Research Team
X
Xixi Yang, MD, PhD
Z
Zheng Liu, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here